QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.

The PROMIS Trial: Using MRI to Avoid Unnecessary Biopsies

Typically, men with elevated PSAs have transrectal ultrasound-guided (TRUS) prostate biopsies to look for prostate cancer. However, TRUS biopsies can have errors in diagnosis because tissue samples are taken at random, and they cannot confirm whether a cancer is aggressive…

Read More

Midlife Baseline PSA Predicts: Lethal Prostate Cancer

A case-control study found that a midlife PSA above the median strongly predicted future lethal prostate cancer. The authors suggested that risk-stratified screening on the basis of midlife PSA should be considered for men ages 45 to 59 years. The…

Read More

Subscribe to Quest